Check for updates

OPEN ACCESS

EDITED BY Javier Echeverria, University of Santiago, Chile

REVIEWED BY Yunshan Wu, Guangzhou University of Chinese Medicine, China Hui Cui, Guangzhou University of Chinese Medicine, China

*CORRESPONDENCE Cong Huang, in huangcong236@163.com Ming-hong Dong, in dmh99102@163.com

RECEIVED 05 September 2024 ACCEPTED 25 November 2024 PUBLISHED 03 January 2025

CITATION

Luo L-y, Zhang X-d, Mei H-m, Ma J-h, Peng X, Dong M-h and Huang C (2025) Miao medicine Tiekuaizi (*Radix Chimonanthi*): a review of its traditional uses, phytochemistry, pharmacology, and predictive analysis on quality markers. *Front. Pharmacol.* 15:1491585. doi: 10.3389/fphar.2024.1491585

COPYRIGHT

© 2025 Luo, Zhang, Mei, Ma, Peng, Dong and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Miao medicine Tiekuaizi (*Radix Chimonanthi*): a review of its traditional uses, phytochemistry, pharmacology, and predictive analysis on quality markers

Li-ying Luo¹, Xu-dong Zhang¹, Hui-min Mei¹, Jian-hui Ma¹, Xin Peng¹, Ming-hong Dong^{1*} and Cong Huang^{1.2*}

¹Guizhou University of Traditional Chinese Medicine, Guiyang, China, ²Anshun Hospital of Traditional Chinese Medicine, Anshun, China


Miao medicine Tiekuaizi (*Radix Chimonanthi*) has been successfully used by Guizhou Miao ethnic physicians in clinical treatments, demonstrating significant curative effects. The research progress on the resource distribution, traditional uses, phytochemistry, and pharmacology of Tiekuaizi was reviewed by collecting related literature from traditional Chinese medicine books and various databases. Based on the comprehensive review and centered around the principles of traditional Chinese medicine quality marker (Q-Marker) theory, nine secondary metabolites (scopoletin, scopolin, isofraxidin, fraxin, scoparone, calycanthoside, 6, 7, 8-trimethoxycoumarin, tomenin, and calycanthine) are suggested as potential Q-markers for Tiekuaizi to establish quality control standards. This can provide a valuable reference for the collection and processing, pharmaceutical production, and effectiveness and safety of clinical applications of Miao medicine Tiekuaizi.

KEYWORDS

Miao medicine Tiekuaizi, Radix Chimonanthi, phytochemistry, pharmacology, quality marker

1 Introduction

Miao medicine Tiekuaizi (*Radix Chimonanthi*) is the dried fine root of *Chimonanthus praecox* (L.) Link and *Chimonanthus nitens* Oliv, a genus of Calycanthaceae, a characteristic ethnic medicine of Guizhou, with the effect of removing wind and alleviating pain (QuFengZhiTong) and circulating blood and removing toxins (HuoXueJieDu). It is used for treating asthma, strain and cough, stomach pain, abdominal pain, rheumatism, paralysis, boils and swellings, bruises, injuries, etc. It has been widely used in clinics and has also formed a large-scale pharmaceutical industry, such as JinGuShang spray, TongLuoGuZhiNing ointment, FuFangXianLingFengShi liquor, ShengLongQuFeng medicinal liquor, FuFangXieTeng medicinal liquor, MaLanGanHan capsules, Liangjiang Weiyang capsules, Ganqing syrup, and other special varieties (Guizhou Provincial Drug Administration, 2019). Tiekuaizi was first recorded in the *Materia Medica* and is also included in *the Chinese Materia Medica* (*Miao Medicine Volume*) (Qiu et al., 2006), *Zhong Yao DaCi Dian* (Nanjing University of Traditional Chinese and Ethnic Medicinal Herb



(Guizhou Provincial Drug Administration, 2019). However, the content only includes the plant source, morphology, and identification of medicinal materials. There are no records of the index ingredients of Miao medicine Tiekuaizi, and there is no standard basis for systematically explaining the relationship between "ingredients – quality – efficacy," which does not meet the requirements of traceability, cultivation, preparation, processing, and quality control. Therefore, the construction of a quality evaluation system that correlates traditional efficacy and clinical efficacy is an important issue for the development of the Tiekuaizi industry and the safety of medicine.

Since the last century, domestic and foreign scholars have studied the genus *Chimonanthus* and found that the genus is rich in volatile oils, coumarins, and flavonoids (Li et al., 2018; Liu et al., 2018; Wang et al., 2012; Shu et al., 2019; Li et al., 2021; He et al., 2023; Lin, 2019). At present, there are many research reports on the properties of leaves of *C. nitens* and *C. praecox*, and many researchers have reviewed their metabolites and pharmacological activities (Ma et al., 2010; Nie et al., 2009; Dong et al., 2021; Yu et al., 2021; Hu and Yang, 2008). However, relatively few studies have been conducted on Tiekuaizi (*Radix Chimonanthi*, roots of *C. nitens* and *C. praecox*). Additionally, geographical differences have resulted in a homonym phenomenon with *Helleborus thibetanus*, a member of the Ranunculaceae family. Therefore, a review of its resource distribution, clinical medication, chemical composition, and pharmacological effects has guiding significance for correct clinical medication.

Literature search was conducted with the keywords "Radix Chimonanthi," "C. praecox," and "C. nitens." from Web of Science (https://webofscience.clarivate.cn), PubMed (https:// pubmed.ncbi.nlm.nih.gov), China National Knowledge Infrastructure (https://www.cnki.net), Wanfang Database (https:// www.wanfangdata.com.cn), and Google Scholar (https://scholar. google.com). Manual reading was performed to eliminate duplicate literature works and irrelevant content in the database. Only the research literature works mentioning the roots of C. praecox and C. nitens as medicinal parts were selected. Based on classic Chinese medicine books and relevant literature collected from various databases mentioned above, all eligible studies were analyzed and summarized. A review was conducted on the resource distribution, usage, phytochemistry, and pharmacological effects of the Miao medicine Tiekuaizi. With the continuous research on Tiekuaizi, coumarins, alkaloids, terpenoids, volatile oils, and other secondary metabolites have been isolated from it (Luo et al., 2023). Modern pharmacological studies have found that it has antiinflammatory effects, analgesic effects, used in treatment of cardiovascular and cerebrovascular diseases, improves disorders of glucolipid metabolism, regulates immunity, and has antitumor and other effects (Li and Zou, 2018; Liu et al., 2018; Wang et al., 2012; Shu et al., 2019; Dong et al., 2021; Yu et al.,

2021; Hu and Yang, 2008). However, no research has been conducted to systematically explain the quality evaluation of Tiekuaizi from the perspective of a quality marker (Q-marker), which limits the establishment of an evaluation system for the scientific quality of Tiekuaizi. Based on the existing research results of Tiekuaizi and the Q-marker theory of Chinese medicine (Liu et al., 2016), this paper analyzes and predicts the Q-marker of Tiekuaizi in terms of metabolite specificity, effectiveness, measurability, quality transfer traceability, and pharmaceutical rule of TCM ("five principles") to provide a scientific basis for the establishment of a better quality evaluation standard of Tiekuaizi of Miao medicine.

2 Resource distribution and ethnic clinical medication

Tiekuaizi is widely distributed in Guizhou, Yunnan, Sichuan, and other provinces, and it also known as Zuangufeng, Yanma Sangen, and Tiegangcha. It has a long history of medicinal use in Guizhou (Guizhou Provincial Drug Administration, 2019; Zhu et al., 2020), and the Guiyang Folk Medicinal Herbs records that its formulations can treat iron injuries, stomach pain, cold abdominal pain, coughs from strain, and blood pockets in the abdomen of women (Guiyang Health Bureau, 1959); according to the Chinese Materia Medica (Miao Medicine Volume), it can treat phuang poisonous sores, strain cough, stomach pain, abdominal pain, rheumatism paralysis, healing sores, swelling and poison, bruises, and injuries. Prepared formulations include Liangjiang Weiyang capsules, FuFangXieTeng medicinal liquor, MaLanGanHan capsules, and Ganqing syrup (Qiu et al., 2006). The Colorful Atlas of Chinese Miao Medicines records that it can treat rheumatic pain, stomach pain, and asthma (Wang, 2002); the Research and Development of Miao Medicine in Guizhou records the treatment of bone fractures and rheumatic joint pain (Bao and Ran, 1999); the Chinese Folklore Hundred Herbs and Prescriptions records the treatment of lumbar muscle strain and cold abdominal pain by grouping prescriptions (Zhou, 1998); Guizhou Folk Remedies Collection records treatment for wind paralysis, rheumatic pain, acute rheumatic arthritis, osteophytes, and conventional and new injuries (Yang and Yang, 1978). Different habitats, climates, and land resources will affect the properties of Tiekuaizi. On the other hand, with the annual development of the Tiekuaizi industry and strong market demand, it is urgent to improve its quality evaluation standards and provide the necessary scientific research base for industrial upgrading.

3 Phytochemistry

Since the last century, many researchers have been studying the secondary metabolites of the genus *Chimonanthus*. There have been many literature reports on the secondary metabolites from the leaves of *C. nitens and C. praecox*, but there have been relatively few reports on the research of roots (the medicinal part of Tiekuaizi). At present, more than 100 secondary metabolites have been isolated and identified from Tiekuaizi, including non-volatile compounds such as coumarins (No. 1–19), terpenoids (no. 20–27), and others (no. 28–36) and volatile oils

(no. 37–105). Metabolite information can be found in Tables 1, 2. The structure of the non-volatile secondary metabolites obtained from Tiekuaizi is shown in Figure 1. Among them, coumarins, represented by scopoletin, are important pharmacodynamic markers of Tiekuaizi and have attracted attention due to their significant anti-inflammatory and analgesic effects.

3.1 Non-volatile secondary metabolites

3.1.1 Coumarins

Coumarins are widely found in the roots, stems, leaves, flowers, fruits, and seeds of higher plants and in animals and microorganisms. It is an important natural medicine and an important secondary metabolite for the study of Chinese and ethnic medicines. Coumarins often have hydroxyl and alkoxy substitutions on the parent nucleus, and the main metabolic modes include sulfonation, reduction reactions, and acidification of glucuronides (Kuang, 2023). Modern pharmacology has found that coumarins have a wide range of biological activities. Miao medicine Tiekuaizi mainly contains coumarins, which have antiinflammatory, analgesic, and antibacterial effects (Zhao et al., 1993; Li, 2008; Zhang, 2013; Qian, 2016). Many coumarins obtained from the roots of C. praecox have been isolated and identified, including scopoletin, scopolin, 6,8-dimethoxy-7-hydroxycoumarin, 6,7,8trimethoxycoumarin, 6,7-dimethoxycoumarin, tomenin. isozinpyridine, isozinpyridine 7-O-β-D-glucoside, 7-hydroxy-6methoxy-chroman-2-one, and praecoxin, of which praecoxin is a new coumarin isolated by our research group (Qian, 2016).

In recent years, researchers have also studied the secondary metabolites of the roots of *C. nitens*. Li et al. (2013) isolated two new coumarins, namely, nitensosides A–B, and five known coumarins from them and determined their antibacterial activity.

Tan et al. (2017) first developed a method based on a modified mass defect filter (MDF) and performed a comprehensive analysis of coumarins from different medicinal parts of *C. nitens* by ultra-high liquid chromatography-tandem quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). The MDF-based five-point screening method and the visual isotope ion technique allow rapid screening of precursor ions of interest. The mass spectrometry fragmentation patterns of coumarins were systematically studied, and 32 coumarins, including 19 potential new coumarins, were initially identified unequivocally in *C. nitens* roots. In 2020, Wang (2020) isolated 10 coumarins from the roots of *C. nitens* and compared the changes in the contents of four metabolites, namely, scopolin, fraxin, scopoletin, and isofraxidin, after drying in the shade, stoving, steaming, and carbonization.

Comparative analysis shows that the abundance of coumarins in the roots of *C. praecox* and *C. nitens*, among which there are eight co-contained coumarins, including scopoletin, scopolin, isofraxidin, fraxin, scoparone, calycanthoside, 6, 7, 8-trimethoxycoumarin, and tomenin.

3.1.2 Terpenoids

In 2018, Lou et al. (2018) isolated four new (Chimonol A–D) and four known sesquiterpenoids (oxyphyllenodiol A, oxyphyllenodiol B, muurolane- 2β , and 9β -diol-3-ene and (+)-t-cadinol) from the roots of *C. nitens*. The antimicrobial activity

Category	No.	hemical composition of Tiekuaizi. Metabolites	Formula	CAS	Source	Ref.
Coumarins	1			92-61-5	C	
Coumarins	1	Scopoletin	C ₁₀ H ₈ O ₄	92-61-5	C	Li, D., (2008); Li, Q.J. et al. (2013); Tan, T. et al. (2017); Wang, X., (2020); Zhang, Y. (2013); Zhao, H.R. et al. (1993)
	2	Scopolin	C ₁₆ H1 ₈ O ₉	531-44-2	С	Li, D., (2008); Li, Q.J. et al. (2013); Tan, T. et al. (2017); Wang, X. (2020); Zhao, H.R. et al. (1993)
	3	Fraxin	$C_{16}H_{18}O_{10}$	524-30-1	С	Tan, T. et al. (2017); Wang, X. (2020); Zhang, X.D. et al. (2024)
	4	Isofraxidin	$C_{11}H_{10}O_5$	486-21-5	С	Tan, T. et al. (2017); Wang, X. (2020); Zhang, Y. (2013); Zhang, X.D. et al. (2024)
	5	Calycanthoside	C ₁₇ H ₂₀ O ₁₀	483-91-0	С	Li, D. (2008); Li, Q.J. et al. (2013); Zhang, Y. (2013)
	6	Scoparone	C ₁₁ H ₁₀ O ₄	120-08-1	С	Li, D. (2008); Tan, T. et al. (2017); Wang, X. (2020); Zhang, Y. (2013)
	7	6, 7, 8-Trimethoxycoumarin	C ₁₂ H ₁₂ O ₅	6035-49-0	С	Li, D. (2008); Tan, T. et al. (2017); Zhang, Y. (2013)
	8	Xeroboside	C ₂₁ H ₂₆ O ₁₃	117,842- 09-8	А	Li, Q.J. et al. (2013); Wang, X. (2020)
	9	Nitensoside A	C ₂₁ H ₂₆ O ₁₄	-	А	Li, Q.J. et al. (2013); Wang, X. (2020)
	10	Nitensoside B	C ₂₃ H ₃₀ O ₁₅	-	А	Li, Q.J. et al. (2013); Tan, T. et al. (2017)
	13	Magnolioside	C ₁₆ H ₁₈ O ₉	20,186-29-2	А	Tan, T. et al. (2017)
	11	5, 6, 7-Trimethoxycoumarin	C ₁₂ H ₁₂ O ₅	55,085-47-7	А	Li, Q.J. et al. (2013); Wang, X. (2020)
	13	Tomenin	C ₁₇ H ₂₀ O ₁₀	28,446-08-4	С	Li, D. (2008); Tan, T. et al. (2017)
	14	Clemiscosin A	C ₂₀ H ₁₈ O ₈	76,948-72-6	А	Tan, T. et al. (2017)
	15	Clemiscosin C	C ₂₁ H ₂₀ O ₉	84,575-10-0	А	Tan, T. et al. (2017)
	16	7-Hydroxy-6-methoxy-chroman-2-one	C ₁₀ H ₁₀ O ₄	90,843-91-7	В	Zhang, Y. (2013)
	17	Arteminorin A	C ₂₂ H ₁₈ O ₁₀	1,158,294- 42-8	А	Tan, T. et al. (2017)
	18	7-O-(6-O-syringoyl-β-D-glucopyranosyl)- 6-methoxycou-marin	$C_{25}H_{26}O_{13}$	1,820,924- 13-7	А	Wang, X. (2020)
	19	Praecoxin	C ₂₁ H ₂₂ O	1,698,917- 27-9	В	Qian, H.B. (2016); Zhang, X.D. et al. (2024)
Terpenoids	20	Chimonol A	C ₁₉ H ₃₀ O ₆	1,574,775- 65-7	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
	21	Chimonol B	$C_{17}H_{28}O_5$	1,574,775- 69-1	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
	22	Chimonol C	C ₁₅ H ₂₄ O ₃	1,569,669- 10-4	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
	23	Chimonol D	C ₁₅ H ₂₄ O ₃	1,569,669- 08-8	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
	24	Oxyphyllenodiol A	C ₁₄ H ₂₂ O ₃	363,610- 30-4	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
	25	Oxyphyllenodiol B	C ₁₄ H ₂₂ O ₃	363,610- 32-6	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
	26	Muurolane-2 β , 9 β -diol-3-ene	C ₁₅ H ₂₆ O ₂	23,971-80-4	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
	27	(+)-t-cadinol	C ₁₅ H ₂₆ O	58,580-31-7	В	Lou, H.Y. et al. (2018); Zhang, Y. (2013)
Others	28	(+) - calycanthine	$C_{22}H_{26}N_4$	595-05-1	С	Li, D., (2008); Li, Q.J. et al. (2013); Wang, X. (2020); Zhao, H.R. et al. (1993)
	29	Chimonanthine	C ₂₂ H ₂₆ N ₄	5545-89-1	В	Zhao, H.R. et al. (1993)
	1	1	1	1	1	I

TABLE 1 Non-volatile chemical composition of Tiekuaizi.

(Continued on following page)

Category	No.	Metabolites	Formula	CAS	Source	Ref.	
	30	β -Sitosterol	C ₂₉ H ₅₀ O	83-46-5	С	Li, D., (2008); Zhang, Y. (2013); Wang, X. (2020); Zhao, H.R. et al. (1993)	
	31	Daucosterol	C35H60O6	474-58-8	В	Li, D., (2008); Zhao, H.R. et al. (1993)	
	32	Sitostenone	C ₂₉ H ₄₈ O	1058-61-3	В	Zhang, Y. (2013)	
	33	Liriodendrin	$C_{34}H_{46}O_{18}$	573-44-4	А	Wang, X. (2020)	
	34	Syringic acid	$C_9H_{10}O_5$	530-57-4	В	Zhang, Y. (2013)	
	35	Glucosyringic acid	$C_{15}H_{20}O_{10}$	33,228-65-8	А	Wang, X. (2020)	
	36	Tetratriacontane	C34H70	14,167-59-0	В	Li, D. (2008)	

TABLE 1 (Continued) Non-volatile chemical composition of Tiekuaizi.

A is the roots of C. nitens; B is the roots of C. praecox; C is the roots of C. nitens and C. praecox

was evaluated by determining the minimum inhibitory concentrations (MICs) using the micro-broth dilution method.

3.1.3 Others

Except for the above coumarins and terpenoids, Tiekuaizi also contains alkaloids, steroids, and phenolic acids (Zhao et al., 1993; Li, 2008; Wang, 2020), such as (+)-calycanthine, chimonanthine, β -sitosterol, daucosterol, sitostenone, liriodendrin, syringic acid, glucosyringic acid, and tetratriacontane. Some flavonoids are also present in Tiekuaizi, and Duan et al. (2013) studied the mechanism by which the total flavonoids of Tiekuaizi delay *D*-galactose-induced aging, possibly in relation to scavenging free radicals in the body and improving immune function. However, the isolation and identification of the flavonoid metabolites in Tiekuaizi have not been reported.

3.2 Volatile oils

Volatile oils are a mixture with complex secondary metabolites, ranging from tens to hundreds. The components of volatile oils are most commonly terpenoids, together with small non-terpenoid aliphatic and aromatic compounds (Kuang, 2023). Tiekuaizi has a pungent and aromatic flavor. The volatile oils in Tiekuaizi are mainly found in the phloem. Wang et al. (2010) identified 36 secondary metabolites from the volatile oil of the roots of *C. nitens* using GC–MS, with higher contents of cineole (25.29%), terpinine-4-ol (13.07%), linalyl propionate (10.50%), camphor (7.27%), oleic acid (6.98%), borneol (4.17%), and sabinene (4.10%).

Gao et al. (2011) and Lu et al. (2021) successively analyzed the components of the volatile oil from the roots of *C. praecox* using the GC–MS method, and 30 and 33 secondary metabolites were detected, respectively, with the main metabolites being the same, including palmitic acid, linoleic acid, oleic acid, and α -cadinol. In contrast, Lu et al. (2021) did not detect the following eight metabolites: aromadendrene, α -amorphene, germacrnen B, α -muurolene, α -cubebene, patchouli alcohol, myristic acid, and pentadecanoic acid) and detected the following ten more metabolites containing hexanal, 2-heptanone, camphor, myrcene, *p*-cymene, *dl*-limonene, methyl salicylate, myrtenol, and myrtenal.

Comparative analysis of the volatile oil metabolites in *C. praecox* and *C. nitens* showed significant differences, with only camphor,

lauricene, α -rossierene, and oleic acid being the co-contained volatile oils, as shown in Table 2.

In summary, Tiekuaizi is rich in volatile oils, coumarins, alkaloids, and terpenoids. Tiekuaizi is a multi-resource Chinese medicine from two species, C. praecox and C. nitens, in the Chimonanthus genus, and the secondary metabolites of Tiekuaizi have not been fully studied from the number of compounds. Based on the existing research of Tiekuaizi, there are only 14 co-contained components, including 10 non-volatile secondary metabolites (No. 1-7, No. 13, No. 28, and No. 30) and four volatile oils (No. 42, No. 47, No. 60, and No. 70). The roots of C. praecox and C. nitens are used as Tiekuaizi for clinical medicine. The quality control of cocontained metabolites and the correlation between co-contained metabolites and drug efficacy need to be studied. In addition, according to the research reports on the secondary metabolites of the other medicinal parts of C. nitens and C. praecox (stems, leaves, flowers, seeds, etc.) (Li et al., 2021), it can be observed that the roots are very different from the other parts. In the future, a modern highthroughput component identification technology can be used to explore the commonality and differences of secondary metabolites in different medicinal parts of the two plants and combined with pharmacological research to study the therapeutic material basis of Tiekuaizi.

4 Pharmacological effects

Modern pharmacology has shown that Miao medicine Tiekuaizi has pharmacological effects including anti-inflammatory, analgesic, immune-regulating, and anti-tumor effects; treating cardiovascular and cerebrovascular diseases; and improving disorders of glycolipid metabolism (Table 3). The pharmacologically active metabolites are coumarins, volatile oils, and so on. The main active monomers are the coumarin compounds such as scopoletin, scopolin, isofraxidin, and fraxin.

4.1 Anti-inflammatory and analgesic effects

The alcohol extract of Tiekuaizi can significantly reduce the levels of hypoxia-inducible factor 1-subunit alpha (HIF-1 α) and tumor necrosis factor- α (TNF- α) in the serum, as well as the

TABLE 2 Composition of volatile oils in Tiekuaizi.

C. nitens			C. praec	cox	
No.	Metabolites	Molecular formula	No.	Metabolites	Molecular formula
No.	Metabolites	Molecular formula	No.	Metabolites	Molecular formula
37	α-Thujene	C ₁₀ H ₁₆	71	Camphene	C ₁₀ H ₁₆
38	α-Pinene	C ₁₀ H ₁₆	72	1, 8-Cineole	C ₁₀ H ₁₈ O
39	Camphene	C ₁₀ H ₁₆	73	L-Linalool	C ₁₀ H ₁₈ O
40	Sabinene	C10H16	74	(-)-Borneol	C ₁₀ H ₁₈ O
41	β-Pinene	C10H16	75	Endobornylacetate	C ₁₂ H ₂₀ O ₂
42	β-Myrcene	C ₁₀ H ₁₆	76	α-Copaene	C ₁₅ H ₂₄
43	α-Terpinene	C ₁₀ H ₁₆	77	Calamenene	C ₁₅ H ₂₂
44	4-Isopropyltoluene	C ₁₀ H ₁₄ O	78	Seychellene	C ₁₅ H ₂₄
45	Cineole	C ₁₀ H ₁₈ O	79	α-Humulene	C ₁₅ H ₂₄
46	y-Terpinene	C ₁₀ H ₁₆	80	Aromadendrene	C ₁₅ H ₂₄
47	Camphor	C ₁₀ H ₁₆ O	81	Germacrnen B	C ₁₅ H ₂₄
48	Borneol	C ₁₀ H ₁₈ O	82	α-Muurolene	C ₁₅ H ₂₄
49	Terpinine-4-ol	C ₁₀ H ₁₈ O	83	y-Cadinene	C ₁₅ H ₂₄
50	Linalyl propionate	C ₁₃ H ₂₂ O ₂	84	δ-Cadinene	C ₁₅ H ₂₄
51	L-Menthol	C ₁₀ H ₁₈ O	85	α-Calacorene	C ₁₅ H ₂₀
52	β-Citronellol	C ₁₀ H ₂₀ O	86	Nerolidol	C ₁₅ H ₂₀
53	Geraniol	C ₁₀ H ₁₈ O	87	Caryophyllene oxide	C ₁₅ H ₂₄ O
54	Bornyl acetate	C ₁₂ H ₂₀ O ₂	88	α-Cubebene	C ₁₅ H ₂₄
55	α-Copaene	C ₁₅ H ₂₄	89	α-Cadinol	C ₁₅ H ₂₆ O
56	Geranylacetate	C ₁₂ H ₂₀ O ₂	90	T-muurolol	C ₁₅ H ₂₆ O
57	β-Caryophyllen	C ₁₅ H ₂	91	Patchouli alcohol	C ₁₅ H ₂₆ O
58	Seychellene	C ₁₅ H ₂₄	92	Myristic acid	C ₁₄ H ₂₈ O ₂
59	β -Patchoulene	C ₁₅ H ₂₄	93	Pentadecanoic acid	C ₁₅ H ₃₀ O ₂
60	α-Amorphene	C ₁₅ H ₂₄	94	Palmitoleic acid	C ₁₆ H ₃₀ O ₂
61	Germacrene	C ₁₅ H ₂₄	95	Palmitic acid	C ₁₆ H ₃₀ O ₂
62	Naphthalene	C ₁₅ H ₂₄	96	Linoleic acid	C ₁₆ H ₃₂ O ₂
63	δ-Cadinene	C ₁₅ H ₂₄	97	Stearic acid	C ₁₈ H ₃₆ O ₂
64	α-Calacorene	C ₁₅ H ₂₀	98	Hexanal	C ₆ H ₁₂ O
66	Xanthophyll	C ₁₅ H ₂₆ O	99	2-Heptanone	C ₆ H ₁₂ O
67	Azulene	C ₁₅ H ₂₄	100	Heptanal	C ₇ H ₁₄ O
68	Valencene	C ₁₄ H ₁₈ O	101	<i>p</i> -Cymene	C ₁₀ H ₁₄
69	Palmitic acid	C ₁₆ H ₃₂ O ₂	102	<i>dl</i> -Limonene	C ₁₀ H ₁₆
70	Oleic acid	$C_{18}H_{34}O_2$	103	Methyl salicylate	C ₈ H ₈ O ₃
			104	Myrtenol	C ₁₀ H ₁₆ O
			105	Myrtenal	C ₁₀ H ₁₄ O
			42	Myrcene	C ₁₀ H ₁₆

(Continued on following page)

C. nitens			C. praecox			
No.	Metabolites	Molecular formula	No.	Metabolites	Molecular formula	
			47	Camphor	C ₁₀ H ₁₆ O	
			60	α-Amorphene	$C_{15}H_{24}$	
			70	Oleic acid	C ₁₈ H ₃₄ O ₂	

TABLE 2 (Continued) Composition of volatile oils in Tiekuaizi.

expression of joint matrix metallo proteinase-3 (MMP-3) and vascular endothelial growth factor (VEGF) related to joint swelling and destruction, in the treatment of arthritis in rats (Li et al., 2017; Li and Qian, 2016; Shan et al., 2023; Zhang et al., 2024). In the treatment of rats, a model of myocardial ischemia, the alcoholic extract of Tiekuaizi reduced the expressions of interleukin-18 (IL-18), interleukin-6 (IL-6), and TNF- α and was able to protect against myocardial cell injury produced by inflammatory cell infiltration (Li et al., 2019). The volatile oil of Tiekuaizi significantly inhibited ear swelling in a model of xylene-induced auricular swelling in mice, and it also inhibited the swelling and granulation of the foot and plantar area in mice caused by carrageenan, showing definite anti-inflammatory effects (Qian et al., 2012b; Qian et al., 2012c).

The extracts from various parts of Tiekuaizi have analgesic and anti-inflammatory effects (Zhang, 2013). The analgesic effect was best in the high-dose group at the ethyl acetate site, followed by the lowdose group at the petroleum ether site; the anti-inflammatory effect was best in the low-dose group at the water site, followed by the highdose group at the ethyl acetate site. In terms of analgesia, the Tiekuaizi alcoholic extract and volatile oil reduces the acetic acid-induced writhing response in mice and significantly increases the pain threshold in the heat radiation tail-flick test and hot plate method in mice (Qian et al., 2010; Qian et al., 2012d; Qian et al., 2012a).

Our research team discovered coumarin monomer compound Q-1 (praecoxin) in the previous study on Tiekuaizi, which can inhibit MAPK and NF- κ B signaling pathways and reduce the expressions of inflammatory factors such as IL-6 and TNF- α , and it can also inhibit the cell proliferation of human rheumatoid arthritis (RA) fibroblast-like synovial cell lines, exerting an anti-rheumatoid arthritis effect (Wu et al., 2021).

Tiekuaizi has good anti-inflammatory and analgesic effects as it is rich in coumarins. Studies have shown that coumarin metabolites, such as scopoletin, isofraxidin, and fraxin, can mostly inhibit histamine, NF-κB, and MAPK pathways; inhibit the release of cellular inflammatory factors such as IL-1 β , IL-6, and TNF- α ; and avoid excessive activation of the immune system, resulting in powerful anti-inflammatory effects (Wei et al., 2009).

4.2 Myocardial protective effect

The alcohol extracts of Tiekuaizi can reduce triglyceride and low-density lipoprotein levels and increase high-density lipoprotein levels in a model of myocardial ischemia in rats, achieving lipidlowering effects. It also reduces serum creatine kinase (CK) CK-MB and CK-MM levels; decreases the expression of $TNF-\alpha$, IL-6, and IL- 18 during myocardial ischemia; and reduces myocardial damage caused by ischemia (Li et al., 2019).

The Tiekuaizi alcohol extract can downregulate $I\kappa B-\alpha$, NF- $\kappa Bp65$, and NF- $\kappa Bp50$ mRNA and protein expressions, inhibit the activation of the NF- κB signaling pathway, reduce the inflammatory response, and play a cardioprotective role, which has a good protective effect on the cardiac function of rats in a myocardial ischemic model (Xu et al., 2022). Studies have shown that the coumarin analog isofraxidin alleviates myocardial infarction by inhibiting NLRP3 inflammasome activity (Chen et al., 2020).

4.3 Anti-viral and anti-bacterial effects


The volatile oil of the roots of *C. praecox* has the strongest antibacterial activity, and the compositional analysis showed mainly more monoterpenes than in the leaves and peel. It is possible that this metabolite is the active metabolite of the root volatile oil in inhibiting fungi, especially against pathogenic fungi and Grampositive bacteria, with a broader spectrum of inhibitory activities (Wang et al., 2009). It is, therefore, customary in folklore to use Tiekuaizi for inflammatory conditions of the gastrointestinal tract, presumably in relation to its strong antibacterial properties.

In an *in vitro* test, the metabolite calycanthine found in Tiekuaizi showed significant inhibitory activity against five phytopathogenic fungi *Exserohilum turcicum, Bipolaris maydis, Alternaria solani, Sclerotinia sclerotiorum, and Fusarium oxysporum,* with *B. maydis* being the most sensitive with an EC50 value of 29.3 mg mL⁻¹ (Zhang et al., 2009).

The metabolites chimonol C, chimonol D, oxyphyllenodiol A, oxyphyllenodiol B, muurolane-2 β , and 9 β -diol-3-ene, isolated from *C. praecox* roots, showed inhibitory activity against *Staphylococcus smoothus* (ATCC 2001) and *Staphylococcus aureus* (ATCC 43300) with MIC values of 128–197 µg mL⁻¹. The metabolite chimonol A–D showed antibacterial activity against *S. aureus* (ATCC 25923) with MIC values of 162–254 µg mL⁻¹ (Lou et al., 2018).

4.4 Anti-tumor effects

In cell proliferation inhibition experiments, it was found that Tiekuaizi could significantly inhibit the growth and proliferation of BGC-823 tumor cells *in vitro*, and the inhibitory effect was positively correlated with the concentration (Lu et al., 2021). It has been reported that isofraxidin can synergistically produce anti-tumor effects by blocking the tumor cell cycle in the G2/M phase, inducing apoptosis, and reducing tumor cell invasion (Chen et al., 2016; Li et al., 2018).



4.5 Immune regulation

When immunity is disturbed, it can cause severe hypersensitivity reactions and diseases such as RA and immunodeficiency. Tiekuaizi, on the other hand, has a good immunoprotective effect and can enhance the immune capacity of immunosuppressed mice, increase the thymic index and the body weight of immunosuppressed mice, and enhance hypersensitivity reactions by a mechanism related to the increased secretion of expression factors such as IL-6, $TNF-\alpha$, IgM, and complement

Activity	Sample	Model/Assay	Dosage	Positive control drug	Effect/mechanism	Ref.	
Anti-aging	Total flavonoids	<i>D</i> -galactose induced aging in mice	High: 5 g/kg/d Low: 2.5 g/kg/d (continuous administration for 3 weeks)	Vit E: 0.1 g/k/d	Total flavonoids of Tiekuaizi can increase the index of thymus, spleen, and brain in mice. It is suggested that enhancing immunity may be one of the ways to delay aging of total flavonoids of Tiekuaizi.	Duan et al. (2013)	
Anti-cancer	Volatile oil	Human gastric cancer cells BGC-823	300, 150, 75, 35, and 15 μL/ mL (the drug acts on the cells for 24 h)	Capecitabine: 0, 0.25, 0.5, 1.0,2.0, and 4.0 µL/mL	The volatile oil of <i>Chimonanthi Radix</i> could inhibit the growth of BGC-823 cells. Human gastric cancer cells BGC-823: $IC_{50} = 11.793 \mu$ L/mL.	Lu et al. (2021)	
	Isofraxidin	Breast cancer stem cells	0, 17, 50, 150, and 450 μmol/L	N/A	Isofraxidin can downregulate the expression of the Bcl-2 gene and activate the caspase gene. Family can induce apoptosis of breast cancer stem cells and inhibit their proliferation and migration at the same time.	Li et al. (2018)	
Anti- inflammatory	Alcohol extract	Adjuvant arthritis rats	High: 7.0 g/kg/d Middle: 3.5 g/kg/d Low: 1.75 g/kg/d (the drug was administered once daily for 30 days)	Tripterygium wilfordii glycoside tablets: 31.5 mg/kg/d	The alcohol extract of Tiekuaizi can inhibit the foot swelling of AA rats and reduce the concentration of TNF- α and PAF in serum.	Li et al. (2017)	
					Alcohol extract of Tiekuaizi downregulates the expressions of HIF-1 α , VEGF, and MMP-3.	Li and Qian (2016)	
	Volatile oil		High: 10.0 g/kg Middle: 5.0 g/kg Low: 2.5 g/kg (continuous administration for 21 days)	Fengshi Gutong Capsule suspension: 0.2 g/kg	The volatile oil of Tiekuaizi can significantly inhibit the contents of IL -1 β and TNF- α in serum of AA rats, reduce foot swelling and eliminate inflammation.	Qian et al. (2012b)	
		Mouse ear swelling model	High: 20 g/kg Middle: 10 g/kg Low: 5 g/kg (continuous administration for 21 days)	Aspirin: 0.2 g/kg	The volatile oil of Tiekuaizi has good anti-inflammatory effects on acute, early and late inflammation.	Qian et al. (2012c)	
	Aqueous extract	·	Osteoarthritis rats	High: 150 mg/kg Middle: 50 mg/kg Low: 16.5 mg/kg	Celecoxib: 16.7 mg/kg	Tiekuaizi significantly affects the NLRP3 inflammasome, which is regulated by the HIF-1α pathway. Tiekuaizi inhibited pyroptosis and reduced synovial inflammation.	Zhang et al. (2024)
		Collagen-induced arthritis rats	High: 1.0 g/kg/d Middle: 0.5 g/kg/d Low: 0.25 g/kg/d (three times a week, Continuous gavage treatment for 25 days)	Methotrexate: 2.0 mL/kg/d	Tiekuaizi may alleviate the inflammatory response in RA rats through an anti-rheumatoid arthritis mechanism involving the OPG/ RANK/RANKL signaling pathway.	Shan et al. (2023)	
	Fraxin	(Mouse mononuclear macrophage cell line) RAW 264.7 cells	20 μg mL ⁻¹ (the drug acts on the cells for 24 h)	N/A	Fraxin can have anti-inflammatory effects by clearing intracellular reactive oxygen species (ROS), reducing intracellular oxidative stress, inhibiting macrophages to promote M1 phenotype polarization, and promoting anti-inflammatory M2 phenotype polarization.	Wei et al. (2022)	
	Isofraxidin	Osteoarthritis rats	<i>In vitro</i> study: 20 μM 10 μM, and 5 μM <i>In vivo</i> assessment: 20 mg/kg/day	N/A	Isofraxidin inhibits TLR4/of human OA chondrocytes. Activation of MD-2 axis and NF- κ B signal can promote cell proliferation and inhibit LPS induction, leading to inflammation.	Jin et al. (2018)	

TABLE 3 Pharmacological effects of extract or main components in Tiekuaizi.

(Continued on following page)

Activity	Sample	Model/Assay	Dosage	Positive control drug	Effect/mechanism	Ref.
Anti- inflammatory and anti-oxidant	Fraxin	Osteoarthritis chondrocyte induced by LPS	0, 0.3125, 0.625, 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μg/m L (The drug acts on the cells for 24 h)	N/A	Fraxin can inhibit the overexpression of inflammatory factors and catabolic genes, promote the upregulation of cartilage-specific genes, eliminate ROS, and has good anti- inflammatory, antioxidant and protective effects on chondrocytes	Zhan et al. (2021)
Anti- nflammation and analgesia	Compound Q-1	Human rheumatoid arthritis fibroblast synovial cell line (MH7A)	High: 100 mg/L Middle: 50 mg/L Low: 25 mg/L	Methotrexate: 5 μmol/L	The alcohol extract of Tiekuaizi has obvious analgesic effect, and its action site may be the peripheral nerve endings or the central nervous system. Compound Q-1 may inhibit the proliferation and migration of MH7A cells and reduce the secretion of inflammatory cytokines TNF-α and IL-6 by regulating p65 and I κ B α- mediated NF-κ B signal pathway and p38-mediated MAPK signal pathway.	Wu et al. (2021)
Analgesia	Volatile oil	Kunming mice	High: 20 g/kg Middle: 10 g/kg Low: 5 g/kg (the drug was given intragastric once a day for 7 days)	Aspirin: 0.2 g/kg	The LD_{50} of volatile oil of Tiekuaizi 8.50 mL kg ⁻¹ . Tiekuaizi volatile oil can obviously inhibit the writhing reaction of mice and increase the pain threshold of thermal stimulation in mice.	Qian et al. (2012d)
	Alcohol extract	Mouse model of pain	High: 200 mg/kg Middle: 100 mg/kg Low: 50 mg/kg	Tramadol hydrochloride: 15 mg/kg	The alcohol extract of Tiekuaizi has inhibitory effect on a variety of pain models, showing obvious analgesic effect, and has a certain dose and time dependence.	Qian et al. (2010)
Protects the myocardium	Isofraxidin	Rat model of acute myocardial infarction after atherosclerosis	High: 93.1 mg/mL Middle: 46.585 mg/mL Low: 23.293 mg/mL (the drug was administered intragastric once a day for 28 days)	Fufang Danshen dropping pills: 13.5 mg/mL	Isofraxidin by suppressing NLRP3 inflammatory bodies plays a cardioprotective role in myocardial infarction.	Xu et al. (2022)
	Alcohol extract	Myocardial ischemic rat model	High: 465.5 mg/kg Middle: 232.925 mg/kg Low: 119.615 mg/kg (The drug was injected intraperitoneally for 7 days)	Fufang Danshen dropping pills: 67.5 mg/kg	The alcohol extract of Tiekuaizi can reduce the level of serum TNF-α, inhibit the expression of inflammatory factors, play an anti- inflammatory effect, and have a certain protective effect on myocardial ischemia. The indexes of CK-MM, and CK-MB in high, middle and low dose groups of alcohol extract of Tiekuaizi were lower than those in model group.	Li et al. (2019)
Anti-tumor and improves body immunity	Isofraxidin	Liver cancer patient	High: 0.35 mg/kg Middle: 0.25 mg/kg Low: 0.15 mg/kg (Once a day, twice a week)	Chemotherapy, surgery, and other treatments	Isofraxidin can effectively inhibit the growth of MMP-7 and cancer cells in patients with liver cancer and reduce the invasive ability of cancer cells.	Chen et al. (2016)
Enhances immunity	Water decoction	Immunocompromised mouse model	High: 1.00 g/mL Middle: 0.50 g/mL Low: 0.25 g/mL (the drug was administered intragastric once a day for 30 days)	Astragalus granule: 0.50 g/mL	Tiekuaizi can enhance immunity, increase thymus index, macrophage phagocytosis, regulate the levels of cytokines, IgM, complement C3 and C4, and the number of RBC and WBC to enhance immune ability and improve immunosuppression.	Ding et al. (2021)
Lipid-lowering	Scopoletin	Obese mouse model	High: 20 mg/kg Low: 10 mg/kg (The drug was given intragastric once a day for 4 weeks)	Silymarin: 30 mg/kg	Scopoletin can improve the blood lipids and fat accumulation of obese mice induced by HFD- and significantly reduce the cell size of adipose tissue of accessory testis in mice.	Jin et al. (2021)

C3; on the other hand, Tiekuaizi can also act on blood cells and increase the number of peripheral blood leukocytes, while the phagocytic index of phagocytes decreases (Ding et al., 2021).

Research has found that scopoletin, fraxin, and isofraxidin can avoid over-activation of the immune system by inhibiting macrophage polarization, inhibiting NF- κ B and MAPK pathways, and suppressing the release of IL-1 β , IL-6, and TNF- α cellular inflammatory factors (Chu et al., 2019; Wei et al., 2022; Jin et al., 2018). Tiekuaizi has strong regulatory effects on the immune system and contains more than three metabolites. The above research results may provide a theoretical basis for the use of Tiekuaizi in the treatment of autoimmune diseases.

4.6 Anti-aging effects

Tiekuaizi also has anti-aging effects, which can enhance human cognitive and learning abilities. The flavonoids in Tiekuaizi have a delaying effect on d-galactose-induced aging in experimental animals. The anti-aging mechanism of Tiekuaizi is probably through increasing the content of SOD, which enhances the body's anti-aging system and increases the body's ability to remove peroxidized lipid products, thus achieving anti-aging effects. It also achieves the anti-aging effect in experimental animals by reducing the number of free radicals in the body and enhancing the immunity in the body and by reducing the number of free radicals in the body and alleviating the neuroimmune damage to the central nervous system (Duan et al., 2013).

Tiekuaizi volatile oil improved the learning and memory capacity in CCH-induced VCI rats, improved the neuronal cell structure, increased the number of Nisus vesicles in the brain, inhibited apoptosis, upregulated serum BDNF levels and hippocampal ChAT activity, decreased hippocampal AChE activity, activated the BDNF/TrkB/PI3KJAkt signaling pathway, improved exploratory capacity, and increased the liking for novelty in rats (Ding et al., 2022).

4.7 Others

Research studies have shown that scopoletin can significantly reduce the expression of cholesterol-regulatory element-binding proteins 1 alpha (SREBP-1a), peroxisome proliferator-activated receptor γ (PPAR- γ), and other genes in mouse epithelial fat. The expression of genes such as proliferator-activated receptor γ (PPAR- γ) (Jin et al., 2021) reduces lipid synthesis, inhibits α glucosidase and a-amylase activities to lower postprandial glucose, and also inhibits protein tyrosine phosphatase 1B (PTP1B) activity. It also inhibits the expression of protein tyrosine phosphatase 1B (PTP1B) and reduces insulin resistance (Jang et al., 2018), regulating glucolipid metabolism in several ways. Based on the methods and techniques of network pharmacology, it was found that Tiekuaizi mainly treats cerebral ischemic stroke (CIS) through key targets such as NOS3, SRC, and PPARG based on neuroactive ligand-receptor interactions and calcium signaling pathways by promoting revascularization, neuroprotection, and anti-inflammation, which also reflects the characteristics of Chinese medicine such as multi-target and multi-linkage in the treatment of CIS (Wang et al., 2022). In addition, volatile oil is a natural transdermal absorption enhancer that promotes drug absorption, is less irritating to the skin, and can play a certain therapeutic role. It has been found that the drug is more effective when administered transdermally, and volatile oil from Tiekuaizi can be added to microemulsions as a transdermal absorption enhancer, and volatile oils can be combined with microemulsions for better efficacy (Lu et al., 2020).

In summary, Tiekuaizi contains a variety of medicinal metabolites that synergistically induce anti-inflammatory, analgesic, antibacterial and antiviral, cardioprotective, immunomodulatory, and anti-tumor effects through a variety of pathways and has great clinical use. These effects are closely related to its abundance of coumarins, alkaloids, and terpenoids as active components. However, Tiekuaizi is rich in various substances, and current research is not comprehensive. Further in-depth research is needed on the pharmacological substance basis.

5 Toxicity

According to the Guizhou Provincial Drug Administration, quality standards for Chinese herbal medicines and ethnic medicinal materials in Guizhou Province, the Miao medicine Tiekuaizi has slight toxicity. There are reports (Knapp et al., 2023) that acute tonic-clonic seizures, tinnitus, disappearance of pupil light reflex, and abnormal vital signs occurred when sheep consumed the leaves of C. praecox in excess, and it is presumed that the toxicity of Tiekuaizi is related to the large amount of calycanthine detected in the stomach contents. Alkaloids are a class of natural organic compounds containing nitrogen, widely existing in plants, and most of them have strong physiological activities. Poisoning or death can occur when the dose is incorrectly administered (Zhu and Lu, 1992). Toxicity studies on Tiekuaizi showed that the volatile oil of Tiekuaizi could make mice curl up and sleep for approximately 20 min; mild toxicity cases showed abdominal convulsions and severe toxicity cases showed respiratory depression and even death, and the mice's heart, liver, kidney, and other important organs showed no significant changes, with an LD₅₀ value of 8.50 mL/kg. The analysis indicated that the volatile oil of Tiekuaizi has lower toxicity, being equivalent to 850 times the daily clinical dose (15 g) for an adult weighing 60 kg (Qian et al., 2012d). Acute toxicity was detected by the concentration gradient of the alcohol extract (0.25 g/kg, 0.50 g/kg, 1.00 g/kg, 2.00 g/kg, 4.00 g/kg, 8.00 g/kg, and 16.00 g/kg). The results showed that the concentration above 1.00 g/kg could cause death in rats, so 1.00 g/kg was considered the maximum safe dose (Shan et al., 2023). The LD₅₀ values of charcoal products dried in the shade and subjected to stoving, steaming, and carbonization were 4,118.13 3,733.36 mg/kg, 1,643.61 mg/kg, mg/kg, and >10,000 mg/kg, respectively. The toxic reactions were hind limb extension, stiffness and shivering, etc. The target organs may be the central nervous system and the neuromuscular system. By comparing the contents and toxicity of four coumarins across four Tiekuaizi products, it was found that while there was no significant difference in the content of two glucoside toxic metabolites, the levels of these metabolites were significantly reduced, and the carbonized charcoal products were non-toxic

(Wang et al., 2020). Although there is evidence that the toxicity of Tiekuaizi may be related to its volatile oils, coumarins, and alkaloids, these secondary metabolites are also the main active components in Tiekuaizi. Consequently, it remains unclear whether the toxic components of Tiekuaizi are also its pharmacodynamic components. Furthermore, the mechanisms underlying the toxic reactions associated with Tiekuaizi and the detoxification processes following carbonization are also not well understood. For example, what happens to the chemical composition? It is also a direction for further research to find out its toxic components and its toxic mechanism and how to reduce toxicity and enhance or maintain the efficacy of Tiekuaizi.

6 Predictive analysis of quality markers

6.1 Predictive analysis of quality markers based on phylogeny and evidence of secondary metabolite specificity of the original plants

The genus Chimonanthus belongs to Calycanthaceae and is characteristic to China, mainly in the mountainous areas of subtropical river valleys south of the Qinling Mountains, west of the Yunnan-Guizhou Plateau, and north of the Nanling Mountains (Dai, 2012). Chinese scholars have divided the genus into eight species and one variety, including C. nitens, C. praecox, C. salicifolius, C. grammatus, C. baokangensis, C. campanulatus, C. zhejiangensis, C. Grammatus. anhuiensis, C. caespitosa, and C. campanulatus var. guizhouensis (Li et al., 2021). Among them, C. nitens and C. praecox are widely distributed species in Guizhou, and their roots, stems, leaves, flower buds, and fruits are used for medicinal purposes (Li and Zou, 2018). The genus Chimonanthus has been extensively studied due to its rich production of volatile oils, flavonoids, coumarins, and other bioactive metabolites, and these active substances are now widely used in medicine, pesticides, spices, food, and oil (Li and Zou, 2018; Liu et al., 2018). Coumarins are the main physiologically active substances in the medicinal plants of this genus (Li and Zou, 2018; Liu et al., 2018; Wang et al., 2012; Shu et al., 2019). Through the analysis of the genetic relationship, the difference of components, and the endemic characteristics of the genus of Chimonanthus plants, the coumarins in Tiekuaizi can be used as an important basis and feasible way to determine the quality markers.

6.2 Predictive analysis of quality markers based on the correlation between the components and efficacy

The theory of properties and actions of Chinese medicinal is a high-level summary of its properties and characteristics. The "four properties and five flavors" is one of the core contents, and "the five flavors" theory is often used as an important basis in clinical medication and combination of medicines and, therefore, is one of the bases for determining quality markers (Yue et al., 2023). Tiekuaizi is pungent, bitter, and warm in nature, entering the lung, liver, heart, and bladder meridians (Guizhou Provincial Drug Administration, 2019), and it is used for the treatment of rheumatic paralysis, bruises, and swelling pains. In the medicinal theory of Chinese medicine, the therapeutic material basis of "bitter" and "pungent" should have their characteristics and functional properties. The bitter flavor can have drying and expelling effects, and it has the effect of clearing away fire and heat, dipping fire and storing yin, and opening up the bowels. In the relationship between bitter principles and meridians, bitter medicines belong to the lung, liver, and stomach meridians. In the relationship between bitter principles and metabolites, those with bitter flavor mostly contain flavonoids, volatile oils, alkaloids, quinones, and glycosides, while bitter-warm and bitter-cold medicines use volatile oils and alkaloids as the main sources of properties and flavors, respectively (Zhang et al., 2016). "Pungent" has the ability to move and disperse and has the effect of dispersing, moving Qi and blood, etc. It mainly enters the heart, spleen, and lung meridians. The therapeutic material includes alkaloids, volatile oils, terpenoids, and glycosides (Zhang M. et al., 2018). In view of this, the coumarins and their glycosides, flavonoids, alkaloids, and volatile oils in Tiekuaizi are the main material basis for the "pungent and bitter" flavor and for the attribution of meridians, and the Q-markers for Tiekuaizi should be selected among the coumarins and their glycosides, alkaloids, and volatile oils.

Coumarins such as isofraxidin, scopoletin, fraxin, and scopolin are the main therapeutic material basis of Tiekuaizi (Luo et al., 2023), which have been found to have anti-inflammatory and analgesic effects, improve cardiovascular and cerebrovascular diseases, improve disorders of glucose and lipid metabolism, and regulate immunity and anti-tumor effects, which have great similarities with traditional efficacy. Tiekuaizi is commonly used as an ethnic medicine for alleviating rheumatic pain and bruises. Therefore, it is concluded that coumarin metabolites represented by scopoletin, etc., should be the main active ingredients to clear heat and remove toxins, resolve swelling, and alleviate pain and can be considered Q-markers of Tiekuaizi.

6.3 Predictive analysis of quality markers based on measurability

Based on original plant affinities and the correlation between traditional medicinal properties and metabolites, the Tiekuaizi Q-marker was selected mainly among alkaloids, coumarins, and volatile oils. However, the volatile oils are complex, and the two plants contain different metabolites, making them unsuitable for selection as Q-markers. Alkaloids and coumarins are suitable for determination by chromatographic methods. Researchers have established stable and simple methods for the determination of coumarin-like metabolites in Tiekuaizi, including scopoletin, scopolin, isofraxidin, fraxin, and scoparone (Zhong and Feng, 2017; Bai et al., 2010; Tang et al., 2015; Xiao et al., 2019; Zhou et al., 2013). Calycanthoside, 6, 7, 8-trimethoxycoumarin, and tomenin can also be identified by techniques such as LC-MS chromatographic techniques (Li et al., 2013; Wang, 2020). The above substances are both specific and active, while metabolites that can be easily determined by chromatography are more suitable candidates of Q-markers of Tiekuaizi. In addition, the alkaloid component of Tiekuaizi, calycanthine, has also established a

content determination method (Wan et al., 2022). This component shows a good antibacterial effect (Zhang et al., 2009). However, its overdose induces more serious toxic reactions (Knapp et al., 2023), and its toxic-effect relationship needs further study. It is speculated that calycanthine is not only a toxic substance showing slight toxicity but also a pharmacodynamic substance, and it can also be used as a quality marker.

6.4 Predictive analysis of quality markers based on blood-accessible chemical components

In a pharmacokinetic study of the main pharmacodynamic components of Tiekuaizi (Zhang J. et al., 2018), the metabolic reactions of scopoletin and scopolin are similar, with different metabolites in different biological samples. The main metabolic reactions in urine and feces are hydrolysis, isomerization, and reduction, and those in plasma are prototype, hydrolysis, reduction, and glucuronidation. A total of three coumarin prototypes (scopoletin, scopolin, and isofraxidin) and 11 metabolites were identified in the study. Through the identification of metabolite products and analysis of their main metabolic pathways, it was revealed that these three coumarin metabolites underwent metabolic reactions such as glucuronidation, sulfonation, and reduction in rats, which are important blood-entry components. These results can provide the pharmacokinetic reference for the selection of Tiekuaizi Q-markers.

7 Conclusion

In this paper, based on a review of the current status of research on the chemical composition and pharmacological effects of Miao medicine Tiekuaizi from Guizhou, the screening and identification of Q-markers for Tiekuaizi based on their chemical composition, relevance to clinical use, measurable metabolites, traditional medicinal efficacy, and metabolism of blood components was analyzed and validated in the literature and research data, and coumarins, alkaloid metabolites, were suggested as potential Q-markers for Tiekuaizi, such as scopoletin, scopolin, isofraxidin, fraxin, scoparone, calycanthoside, 6, 7, 8-trimethoxycoumarin, tomenin, and calycanthine. This was done to screen and identify Tiekuaizi Q-markers and establish it as the quality control standard, which can provide a reference for the collection and processing, pharmaceutical production, and effectiveness and safety of clinical applications of Miao medicine Tiekuaizi.

8 Discussion

Tiekuaizi has a promising future in anti-inflammatory, immunomodulatory, anti-tumor, hypoglycemic, cardiovascular protection, and anti-viral aspects, but there are still many issues to be resolved in the research on Tiekuaizi. First, the pharmacokinetic and toxicity evaluation of Tiekuaizi metabolites need to be improved. The specific metabolic processes of Tiekuaizi in the body are unclear, and corresponding in vivo pharmacokinetic tests should be carried out to elucidate the absorption, transformation, distribution, and excretion processes of Tiekuaizi in the human body and identify the main pharmacodynamic substance basis for their efficacy. Toxicity evaluation and risk avoidance of Tiekuaizi are also key issues that need to be addressed before clinical application. Preliminary toxicity evaluation and investigation of the relationship between the toxicity and efficacy of Tiekuaizi metabolites should be carried out as extensively as possible in future studies, on the basis of which the effective concentration and safe concentration ranges should be further defined, with a view to providing a reference for rational and safe clinical medication. Second, histological techniques should be used to clarify the mechanism of action of Tiekuaizi metabolites. The current means of research on Tiekuaizi is relatively backward compared to the cutting-edge exploration of mechanisms in recent years. Therefore, on the basis of clarifying the action of Tiekuaizi metabolites, relying on genomics, transcriptomics, proteomics, and metabolomics as well as cutting-edge technologies such as single-cell sequencing and epigenetic assays, multi-dimensional detection and screening of more prominent and in-depth action targets of the active metabolites of Tiekuaizi can provide a more thorough and accurate understanding of its pharmacological mechanism of action.

Author contributions

LL: Investigation, Visualization, Writing-original draft, and Writing-review and editing. XZ: Conceptualization and Writing-review and editing. HM: Conceptualization and editing. Writing-review and JM: Methodology and Writing-review and editing. XP: Formal analysis and Writing-review and editing. MD: Supervision and Writing-review and editing. CH: Funding acquisition, Project administration, Resources, Supervision, and Writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82160805), the Guizhou Provincial Basic Research Program (Natural Science) (No. Qiankehe Foundation-ZK [2021] General 537), the Guizhou Provincial Department of Education Youth Science and Technology Talent Growth Project (Qianjiaohe KYZi [2018] 211), and the Academic New Seedling Program of Guizhou University of Traditional Chinese Medicine (Guikehe Xue Shu Xin Miao[2023] -33).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

Bai, H. Q., Cai, S. H., Xu, L., He, M. Z., Zhang, X. J., Feng, Y. L., et al. (2010). Determination of scopoletin, quercetin, and Calycanthus chinensis Cheng et S. Y. Chang alkaloids in Cyperus rotundus by HPLC. *Chin. Tradit. Herb. Drugs* 41 (03), 486–487. CNKI: SUN: ZCYO.0.2010-03-053.

Bao, J., and Ran, M. X. (1999). Research and development of Miao medicine in Guizhou. Guiyang: Guizhou Science and Technology, Press, 153.

Chen, G. B., Chen, J. L., and Liu, Y. F. (2016). Effect of Isofraxidinin on expression of MMP-7 levels and cancer cell invasion ability of patients with liver cancer. J. Bethune Univ. Med. Sci. 14 (02), 148–151. doi:10.16485/j.issn.2095-7858.2016.02.007

Chen, G. F., Song, X. Z., Lin, D. M., and Xu, P. (2020). Isofraxidin alleviates myocardial infarction through NLRP3 inflammasome inhibition. *Inflammation* 43, 712–721. doi:10.1007/s10753-019-01158-z

Chu, Z. X., Lu, M., and Xiong, S. (2019). Research advances on pharmacological activities and pharmacokinetics of scopoletin. *Chem. Res.* 30 (04), 434–440. doi:10. 14002/j.hxya.2019.04.017

Dai, P. F. (2012) Phylogeography, phylogeny and genetic diversity of *Chimonanthus* (Calycanthaceae). [dissertation/master's thesis] *N.W.U.*

Ding, X. L., Suo, P., and Qian, H. B. (2021). Effects of Miao medicine Iron Chopsticks on immune function in immunosuppressive mice. *Chongqing Med.* 50 (13), 2171–2175. doi:10.3969/j.issn.1671-8348.2021.13.003

Ding, X. L., Xue, D. J., Deng, W. J., Han, C. Y., Liu, X. L., Li, Y., et al. (2022). Effect and mechanism of volatile oil of Chimonanthi Radix on vascular cognitive impairment rats induced by chronic cerebral hypoperfusion. *Chin. Tradit. Herb. Drugs* 53 (17), 5389–5399. doi:10.7501/j.issn.0253-2670.2022.17.015

Dong, R. X., Pan, J. J., Jin, Y., Fang, J., Shi, L. M., and Cheng, K. J. (2021). Research advances on chemical constituents and their pharmacological activities of two kinds of medicinal and edible tea from lindl. *Sci. Technol. Food Ind.* 42 (16), 429–437. doi:10.13386/i.jssn1002-0306.2020090070

Duan, Y. P., Li, Y., and Li, S. Z. (2013). The anti-aging effect of total flavonoids from *Chimonanthus praecox* on aging mice induced by D-galactose. *West Chin. J. Pharm.* 28 (05), 456–458. doi:10.13375/j.cnki.wcjps.2013.05.007

Gao, Y., Jin, F. Y., Wang, X. P., Qian, H. B., and Li, Y. S. (2011). Gas chromatographymass spectrometry analysis of the chemical composition of volatile oil from Qian Tiekuaizi. *Lishizhen Med. Materia Medica Res.* 22 (01), 122–123. doi:10.3969/j.issn. 1008-0805.2011.01.058

Guiyang Health Bureau (1959). Folk medicinal herbs of Guiyang, Guiyang: Guizhou people's publishing house, 242-243.

Guizhou Provincial Drug Administration (2019). Quality standards for Chinese herbal medicines and ethnic medicinal materials in Guizhou Province. *Guiyang Guizhou Sci. Tech.*

He, D. Y., Xiao, W. Y., Li, C., and Zou, Z. R. (2023). Research progress on the composition and pharmacological activity of essential oil from *Chimonanthus* Lindl. *Nat. Prod. R&D* 1-19, 5–28. doi:10.16333/j.1001-6880.2023.9.016

Hu, W. J., and Yang, S. B. (2008). Research advancement on chemical components of *Chimonanthus nitens* and its medical values. *Jiangxi For. Sci. Tech.* (06), 60–62. doi:10. 16259/j.cnki.36-1342/s.2008.06.008

Jang, J. H., Park, J. E., and Han, J. S. (2018). Scopoletin inhibits α-glucosidase *in vitro* and alleviates postprandial hyperglycemia in mice with diabetes. *Eur. J. Pharmacol.* 834, 152–156. doi:10.1016/j.ejphar.2018.07.032

Jin, J., Yu, X., Hu, Z., Tang, S., Zhong, X., Xu, J., et al. (2018). Isofraxidin targets the TLR4/MD-2 axis to prevent osteoarthritis development. *Food & Funct.* 9, 5641–5652. doi:10.1039/c8fo01445k

Jin, L. H., Liu, G. C., Wang, L. H., Yan, Z. A., Xu, C., and Yuan, H. D. (2021). Effect of Scopoletin on lipid metabolism in high-fat diet-induced obese mice. J. Yanbian Univ. Nat. Sci. Ed. 47 (02), 160–164. doi:10.3969/j.issn.1004-4353.2021.02.013

Knapp, C., Van Dyke, T., and Foster, D. (2023). Wintersweet (Chimonanthus praecox) toxicity in 5 sheep. J. Veterinary Intern. Med. 37 (6), 2478–2481. doi:10. 1111/jvim.16905

Kuang, H. X. (2023). Chemistry of traditional Chinese medicine. *Beijing Chin. Tradit. Chin. Med. Press.*

Li, D. (2008) "Research on the chemical composition of the herbs Tiekuaizi and *Pyrola calliantha* Andres in Guizhou,". Guizhou Univ. [dissertation/master's thesis]. doi:10.7666/d.Y1396001

organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Li, H., Chen, J., Li, D., Yu, W. T., Liu, Z. W., and Ni, F. (2018). Inhibition of isofraxidin from sarcandra glabra on the breast cancer stem cells via Bcl-2 and Caspase signaling pathway. *Chin. J. Clin. Pharmacol. Ther.* 23 (08), 886–892. doi:10.12092/j.issn.1009-2501.2018.08.008

Li, M., Li, Y. F., and Qian, H. B. (2017). Effects of alcohol extract from *Chimonanthus* praecox on adjuvant arthritis rats and their mechanisms. *J. Liaoning Univ. Tradit. Chin. Med.* 19 (03), 19–21. doi:10.13194/j.issn.1673-842x.2017.03.005

Li, M., and Qian, H. B. (2016). Effects of alcohol extract from root of wintersweet on expression of HIF-1a, VEGF and MMP-3 in adjuvant arthritis rats. *Chin. Pharmacol. Bull.* 32 (9), 1326–1327. doi:10.3969/j.issn.1001-1978.2016.09.027

Li, Q. J., Wang, M. L., Yang, X. S., Ma, L., and Hao, X. J. (2013). Two new coumarin glycosides from *Chimonanthus nitens. J. Asian Nat. Prod. Res.* 15 (3), 270–275. doi:10. 1080/10286020.2012.762766

Li, S. L., and Zou, Z. R. (2018). Research progress on flavonoids and coumarins from *Chimonanthus* plants and its pharmacological activities. *Chin. Tradit. Herb. Drugs* 49 (14), 3425–3431. doi:10.7501/j.issn.0253-2670.2018.14.032

Li, S. Z., Li, Y., Liu, X. L., Xu, T., Wang, Y., and Qian, H. B. (2021). Phytochemical and pharmacological progress on genus *Chimonanthus* in Guizhou. *Chin. J. Ethnomed. Ethnopharm.* 30 (06), 59–65. doi:10.3969/j.issn.1007-8517.2021.6. zgmzmjyyzz202106013

Li, X. F., Lu, S. D., Chen, M., and Qian, H. B. (2019). Effects of ethanol extracts of Miao medicine iron chopsticks on pathological changes, blood lipids, TNF-alpha, IL-6 and IL-18 in myocardial ischemic rats. *Chin. J. Ethnomed. EthnoPharm.* 28 (22), 22–27. doi:10. 3969/j.issn.1007-8517.2019.22.zgmzmjyyzz201922007

Lin, X. (2019). Progress of research on volatile components in the Chimonanthus praecox. Fujian Agric. Sci. Technol. (07), 57–64. doi:10.13651/j.cnki.fjnykj.2019.07.013

Liu, C. X., Chen, S. L., Xiao, X. H., Zhang, T. J., Hou, W. B., and Liao, M. L. (2016). A new concept on quality marker of Chinese materia medica: quality control for Chinese medicinal products. *Chin. Tradit. Herb. Drugs.* 47 (09), 1443–1457. doi:10.7501/j.issn. 0253-2670.2016.09.001

Liu, L. L., Shen, X., Deng, B. Q., and Zou, Z. R. (2018). Advance in studies on flavinoids, coumarins and pharmacological activity of chinonanthus. *Lishizhen Med. Mat. Med. Res.* 29 (05), 1196–1200. doi:10.3969/j.issn.1008-0805.2018.08.059

Lou, H. Y., Zhang, Y., Ma, X. P., Jiang, S., Wang, X. P., Yi, P., et al. (2018). Novel sesquiterpenoids isolated from *Chimonanthus praecox* and their antibacterial activities. *Chin. J. Nat. Med.* 16 (8), 621–627. doi:10.1016/S1875-5364(18)30100-6

Lu, J., Xie, D., Fan, D. Z., Tang, D. X., and Ruan, J. H. (2020). Study on the transdermal drug delivery effects of Tiekuaizi microemulsion of Miao medicine under different transdermal absorption enhancers. *Lishizhen Med. Mat. Med. Res.* 31 (09), 2121–2124. doi:10.3969/j.issn.1008-0805.2020.09.020

Lu, J., Xie, D., Ruan, J. H., Fan, D. S., Cha, X., and Xin, J. M. (2021). Study on chemical composition of volatile oil of Miao medicine Chimonanthi Radix and its inhibitory effect on BGC-823 cells. *Guizhou Sci.* 39 (01), 26–30. doi:10.3969/j.issn.1003-6563.2021. 01.006

Luo, J. F., Wu, Q. M., Huang, C., and Qian, H. B. (2023). Research prigress of Miao medicine radix chimonanthi praeacccis. *J. Guizhou Univ. Tradit. Chin. Med.* 45 (02), 75–80. doi:10.16588/j.cnki.issn2096-8426.2023.02.015

Ma, X. M., Wu, C. F., and Peng, R. H. (2010). Advance in studies on *Chimonanthus* praecox. Anhui Agric. Sci. 38 (34), 19279–19280+19283. doi:10.13989/j.cnki.0517-6611. 2010.34.114

Nanjing University of Traditional Chinese Medicine (2006). Dictionary of Chinese medicine. Shanghai: Shanghai Sci. Tech., 2617.

Nie, L., Zhai, X. Q., and Jie, D. W. (2009). Current status and progress of research on *Chimonanthus praecox. Shanxi Agric. Sci.* 55 (06), 116–119. doi:10.3969/j.issn.0488-5368.2009.06.047

Qian, H. B. (2016). A compound with anti-inflammatory effect and its preparation method and use. *China CN 104496953 B.08.31*.

Qian, H. B., Luo, K., Long, Q. L., and Jin, F. Y. (2012b). Effects of essential oil from *Chimonanthus praecox* in Guizhou on rat adjuvant arthritis and their mechanisms. *J. Anhui Agric. Sci.* 40 (21), 10834–10836. doi:10.3969/j.issn.0517-6611.2012.21.033

Qian, H. B., Pu, J. S., Wang, L., and Li, S. Z. (2012c). Study on the anti-inflammatory effect of the volatile oil of Tiekuaizi in Miao medicine. *Shi-Zhen Guomao* 23 (08), 1961–1962. doi:10.3969/j.issn.1008-0805.2012.08.051

Qian, H. B., Wang, P. X., Li, Y. S., and Jin, F. Y. (2010). An experimental study on the analgesic effect of the alcoholic extract of the Miao medicine, Tiekuaizi. *Lishizhen Med. Mat. Med. Res.* 21 (12), 3120–3121. doi:10.3969/j.issn.1008-0805.2010.12.037

Qian, H. B., Xu, Y. P., and Jin, F. Y. (2012d). The analgesic effect and acute toxicity of essential oil from *Chimonanthus praecox. J. Anhui Agric. Sci.* 40 (12), 7095–7096. doi:10. 3969/j.issn.0517-6611.2012.12.042

Qian, H. B., Xu, Y. P., Pu, J. S., Wang, L., and Jin, F. Y. (2012a). Study on the analgesic effects and mechanism of the ethanol extracts of TieKuaizi. *West Chin. J. Pharm. Sci.* 27 (03), 262–264. doi:10.13375/j.cnki.wcjps.2012.03.015

Qiu, D. W., Du, J., and Xia, T. H. (2006). *Chinese Miao medicine*. Guiyang: Guizhou Sci. Tech: Press, 457–458.

Shan, W. T., Wang, X., Yang, X. L., Ai, F., Liu, Y., Wei, X., et al. (2023). Exploring the protective effect of helleborus thibetanus franch alcohol extract on bone destruction in CIA rats based on the OPG/RANK/RANKL signaling pathway. *Acta Lab. Anim. Sci. Sin.* 31 (10), 1250–1260. doi:10.3969/j.issn.1005-4847.2023.10.002

Shu, R. G., Wan, Y. L., and Wang, X. M. (2019). Non-volatile constituents and pharmacology of *Chimonanthus*: a review. *Chin. J. Nat. Med.* 17 (3), 161–186. doi:10. 1016/S1875-5364(19)30020-2

Tan, T., Luo, Y., Zhong, C. C., Xu, X., and Feng, Y. L. (2017). Comprehensive profiling and characterization of coumarins from roots, stems, leaves, branches, and seeds of *Chimonanthus nitens* Oliv. using ultra-performance liquid chromatography/ quadrupole-time-of-flight mass spectrometry combined with a modified mass defect filter. J. Pharm. Biomed. Anal. 7 (15), 140–148. doi:10.1016/j.jpba.2017.04.016

Tang, X. S., Jin, F. Y., Zhang, Y., Wang, X. P., and Bai, Y. G. (2015). Determining the content of scopoletin in *Chimonanthus praecox* of Miao ethnomedicine by HPLC. *J. Guiyang Colg. Tradit. Chin. Med.* 37 (06), 24–27. doi:10.3969/j.issn.1002-1108.2015. 06.005

Wan, C. Y., Li, Y. Y., Ma, Y. Y., and Huang, Z. Y. (2022). Simultaneous determination of *chimonanthi* and calycanthine in *chimonanthi* nitentis folium by HPLC. *Drug Eval.* 19 (17), 1035–1038. doi:10.19939/j.cnki.1672-2809.2022.17.03

Wang, L. Y., Zhang, Z. B., Zou, Z. R., and Zhu, D. (2012). Advances of studies on chemical composition and pharmacological activity of *Chimonanthus* lind. *Lishizhen Med. Mat. Med. Res.* 23 (12), 3103–3106. doi:10.3969/j.issn.1008-0805.2012.12.072

Wang, M. L., Wang, D. P., Yang, X. S., and Hao, X. J. (2010). Chemical constituents of the essential oil from different parts of *Chimonanthus nitens* Oliv. distributed in Guizhou. *J. Yunnan Univ.(Edit. Nat. Sci.)* 32 (05), 577–582.

Wang, X. (2020) Study on pharmacodynamic material of *Chimonanthus nitens* Oliv. From Guizhou province [dissertation/master's thesis]. doi:10.27045/d.cnki.ggyyc.2020. 000124

Wang, X., Wang, L., Liao, X., Wang, H. B., Yang, J., Li, Q. Q., et al. (2020). Comparative study on the contents of four compounds from different processed products of Miao medicine *Chimonanthus nitens* and its toxicity. *Chin. Pharm.* 31 (12), 1475–1480. doi:10.6029/j.issn.001-0403.2020.12.13

Wang, Y. (2002). Color Atlas of Chinese Miao medicines. First edition. Guiyang: Guizhou Sci.Tech, 524.

Wang, Y., Xu, T., Wu, S. S., Liu, X. L., and Qian, H. Z. (2022). Molecular mechanism of *Chimonanthus praecox* against cerebral ischemic stroke based on network pharmacology. *J. Shenyang Pharm. Univ.* 39 (09), 1118–1129. doi:10.14066/j.cnki. cn21-1349/r.2020.1203

Wang, Z. F., Zhang, N., Ma, X. P., Yang, J. L., Pan, W. D., and Lin, C. H. (2009). Chemical composition and *in vitro* antibacterial and antifu ngal activity of essential oils from different parts of *Chimonanthus praecox* (linn.) Link. *Chin. J. Mod. Appl. Pharm.* 36 (08), 901–905. doi:10.13748/j.cnki.issn1007-7693.2019.08.001

Wei, H., Jiang, C. L., Qin, Z. N., and Zheng, L. (2022). Effect of fraxin on macrophage polarization induced by lipopolysaccharide. *J. Guangxi Med. Univ.* 39 (04), 569–576. doi:10.16190/j.cnki.45-1211/r.2022.04.010

Wei, L. J., Zhou, J. P., and Dai, Y. (2009). Progress in the study of natural product scopoletin. *Strait Pharm. J.* 21 (04), 10–13.

Wu, S. S., Wang, Y., Xu, T., Liu, X. L., and Qian, H. B. (2021). The inhibitory effect of compound Q-1 on proliferation of MH7A induced by TNF-a and its significance. *Chin. Pharmacol. Bull.* 37 (11), 1554–1558. doi:10.3969/j.issn.1001-1978.2021.11.014

Xiao, Y. H., Lei, D. D., Xu, G. B., Zhou, M., He, X., and Liao, S. G. (2019). Simultaneous determination of seven constituents in Liangjiang Weiyang Capsules by HPLC. *Chin. Tradit. Pat. Med.* 41 (08), 1786–1790. doi:10.3969/j.issn.1001-1528. 2019.08.007

Xu, T., Chen, M., Wang, Y., Wu, S. S., Liu, X. L., and Qian, H. B. (2022). Effects and mechanism of Tiekuaizi alcohol extract in the prevention and treatment of myocardial infarction based on network pharmacology. *Chin. J. Hosp. Pharm.* 42 (19), 2014–2023. doi:10.13286/j.1001-5213.2022.19.09

Yang, J. Q., and Yang, J. Z. (1978). A collection of folk remedies from Guizhou. Guiyang: Guizhou People's Publishing House, 80–110.

Yu, H., Wang, T. Y., Wang, J., and You, X. Q. (2021). Research progress of chemical compositions of *Chimonanthus nitens* Oliv. and their biological activities. *Chin. J. Pharm. Anal.* 41 (09), 1477–1486. doi:10.16155/j.0254-1793.2021.09.01

Yue, Q. X., Sun, Y. F., Yang, S., Du, Q. Q., Jin, C. S., Zhang, W., et al. (2023). Study on quality marker of Paeoniae Radix Alba based on quality transfer process of medicinal materials-decoction pieces-standard decoctions. *Chin. Tradit. Herb. Drugs* 54 (02), 553–560. doi:10.7501/j.issn.0253-2670.2023.02.022

Zhan, Y. T., Qin, Z. N., and Zheng, L. (2021). Effects of fraxin on oxidative stress and inflammatory factors induced by lipopolysaccharide in chondrocytes. *J. Guangxi Med. Univ.* 38 (01), 28–34. doi:10.16190/j.cnki.45-1211/r.2021.01.005

Zhang, J., Wen, Q., Xu, X., Chen, L., Feng, Y. L., Yang, S. L., et al. (2018). *In vivo* metabolism of three coumarins from Chimonanthi Radix based on UHPLC-OTOF-MS/MS. *China J. Chin. Mat. Med.* 43 (21), 4330–4338. doi:10.19540/j.cnki.cjcmm. 20180815.005

Zhang, J. W., Gao, J. M., Xu, T., Zhang, X. C., Ma, Y. T., Jarussophon, S., et al. (2009). Antifungal activity of alkaloids from the seeds of *Chimonanthus praecox. Chem. & Biodivers.* 6, 838–845. doi:10.1002/cbdv.200800089

Zhang, J. Y., Cao, H., Xu, J., Han, L. Q., Gong, S. X., Zhang, T. J., et al. (2016). Expression of bitter taste of Chinese materia medica and its application in clinical compatibility. *Chin. Tradit. Herb. Drugs* 47 (2), 187–193. doi:10.7501/j.issn.0253-2670. 2016.02.001

Zhang, M., Huo, H. R., Wang, P. Q., Dai, L., and Sui, F. (2018). Theoretical origin and review of modern research on medicinal properties of spicy flavor. *Chin. Tradit. Herb. Drugs* 49 (3), 505–511. doi:10.7501/j.issn.0253-2670.2018.03.001

Zhang, X. D., Wu, D. W., Zhang, L. K., Zhang, H. Y., Yang, L. P., Wei, L., et al. (2024). Predicting the potential mechanism of radix chimonanthi pracecocis in treating osteoarthritis by network pharmacology analysis combined with experimental validation. J. Ethnopharmacol. 331, 118231. doi:10.1016/j.jep.2024.118231

Zhang, Y. (2013). Screening and chemical composition of the effective parts of Tiekuaizi from Miao medicine in Guizhou. [dissertation/master's thesis].

Zhao, H. R., Ji, Q. F., Wang, M. S., Zhao, S. X., and Wang, Y. P. (1993). Studies on constituents of roots of *Chimonanthus praecox. J. China Pharm. Univ.* (02), 76–77.

Zhong, C. C., and Feng, Y. L. (2017). HPLC fingerprint analysis of caulis of *Chimonanthus nitens* combined with chemometrics method. *Chin. Pharm. J.* 52 (21), 1944–1947. doi:10.11669/cpj.2017.21.016

Zhou, B., Cui, X. D., Cheng, D., Li, J., Wang, P., and Zheng, P. W. (2013). Simultaneous determination of the content of four active compounds in Shanlamei Gran-ules by RP-HPLC. *Lishizhen Med. Mat. Med.* 24 (11), 2653–2654. doi:10.3969/j. issn.1008-0805.2013.11.032

Zhou, P. (1998). Chinese folk remedies. Changsha: Hunan Sci. Tech, 704.

Zhu, C. X., Zhou, X., and Chen, H. G. (2020). Advances on treatment of rheumatoid arthritis with Miao medicine. *Chin. Mod. Appl. Pharmacol.* 37 (21), 2669–2677. doi:10. 13748/j.cnki.issn1007-7693.2020.21.020

Zhu, T. Z., and Lu, C. Y. (1992). Toxicity and prevention of some alkaloid-containing Chinese medicines. *China J. Chin. Materia Medica* (4), 248–250.